Core Viewpoint - The company Hansai Aitai-B (03378) has seen a rebound of nearly 6%, with a current increase of 5.12%, trading at HKD 18.08, with a transaction volume of HKD 10.4874 million [1] Group 1: Clinical Development - The company announced that its innovative drug, HX111, has received approval from the National Medical Products Administration of the People's Republic of China to conduct clinical trials within China [1] - HX111 is a first-in-class OX40-targeted antibody-drug conjugate (ADC), which has shown overexpression in several malignant tumors compared to normal tissues during preclinical studies, making it a suitable target for ADC [1] - HX111 is the third first-in-class molecule to advance to clinical development, following HX009 and HX044, both of which are bispecific antibody therapies [1] Group 2: Future Plans - The company aims to continue its efforts in clinical development to bring more novel first-in-class (FIC) drugs to market [1]
港股异动 翰思艾泰-B(03378)反弹近6% 创新药HX111获得国家药监局批准临床试验